D.E. Shaw & Co
ALT icon

D.E. Shaw & Co’s Altimmune ALT Stock Holding History

D.E. Shaw & Co’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$613K Sell
201,638
-525,363
-72% -$1.57M ﹤0.01% 4075
2026
Q1 		$2.24M Sell
727,001
-616,582
-46% -$2.62M ﹤0.01% 2831
2025
Q4 		$4.85M Buy
1,343,583
+983,188
+273% +$4.29M ﹤0.01% 2326
2025
Q3 		$1.36M Buy
360,395
+309,137
+603% +$1.19M ﹤0.01% 3251
2025
Q2 		$198K Buy
51,258
+742
+1% +$4.01K ﹤0.01% 4055
2025
Q1 		$253K Sell
50,516
-409,317
-89% -$2.59M ﹤0.01% 3838
2024
Q4 		$3.32M Sell
459,833
-298,171
-39% -$2.28M ﹤0.01% 2314
2024
Q3 		$4.65M Sell
758,004
-4,358
-0.6% -$29.5K ﹤0.01% 2003
2024
Q2 		$5.07M Buy
762,362
+408,012
+115% +$3.01M ﹤0.01% 1834
2024
Q1 		$3.61M Buy
354,350
+64,624
+22% +$657K ﹤0.01% 2149
2023
Q4 		$3.26M Sell
289,726
-441,006
-60% -$1.84M ﹤0.01% 2276
2023
Q3 		$1.9M Buy
730,732
+226,494
+45% +$650K ﹤0.01% 2606
2023
Q2 		$1.78M Buy
+504,238
New +$2.26M ﹤0.01% 2700
2023
Q1 		– Sell
-27,702
Closed -$456K – 4400
2022
Q4 		$456K Buy
+27,702
New +$311K ﹤0.01% 3903
2022
Q3 		– Sell
-169,683
Closed -$1.99M – 5153
2022
Q2 		$1.99M Sell
169,683
-798,053
-82% -$4.92M ﹤0.01% 3088
2022
Q1 		$5.89M Sell
967,736
-213,501
-18% -$1.57M 0.01% 2129
2021
Q4 		$10.8M Buy
1,181,237
+225,799
+24% +$2.4M 0.01% 1599
2021
Q3 		$10.8M Buy
955,438
+127,682
+15% +$1.55M 0.01% 1463
2021
Q2 		$8.15M Sell
827,756
-488,058
-37% -$6.67M 0.01% 1669
2021
Q1 		$18.6M Buy
1,315,814
+122,120
+10% +$1.97M 0.02% 971
2020
Q4 		$13.5M Sell
1,193,694
-467,136
-28% -$5.5M 0.01% 1190
2020
Q3 		$21.9M Buy
+1,660,830
New +$33.2M 0.02% 781
2019
Q3 		– Sell
-12,300
Closed -$29K – 3785
2019
Q2 		$29K Sell
12,300
-800
-6% -$2.14K ﹤0.01% 3608
2019
Q1 		$38K Hold
13,100
– – ﹤0.01% 3526
2018
Q4 		$27K Buy
+13,100
New +$46.4K ﹤0.01% 3699

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co's ALT Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Altimmune (ALT) stake by 72% in Q2 2026, selling an estimated $1.57M and leaving 201,638 shares worth $613K. The position accounts for ﹤0.01% of the portfolio, ranked #4075.

D.E. Shaw & Co first reported a position in ALT in Q4 2018 and has held it in 25 quarters since. The position peaked at $21.9M in Q3 2020. 211 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • D.E. Shaw & Co held 201,638 shares of Altimmune worth $613K as of Q2 2026.
  • D.E. Shaw & Co sold 525,363 Altimmune shares in Q2 2026, an estimated $1.57M.
  • Altimmune made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4075 holding.
  • D.E. Shaw & Co first reported a position in Altimmune in Q4 2018 and has held it in 25 quarters since.
  • D.E. Shaw & Co's Altimmune position peaked at $21.9M in Q3 2020.
  • 211 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.